CNS Pharmaceuticals, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $2.6M | $8.8M | $5.0M |
| FY2022 | $4.9M | $13.1M | $10.1M |
| FY2023 | $6.1M | $1.7M | $548.7K |
| FY2024 | $2.5M | $8.7M | $6.5M |
| FY2025 | $4.1M | $8.6M | $7.2M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $2.6M | $8.8M | $5.0M |
| FY2022 | $4.9M | $13.1M | $10.1M |
| FY2023 | $6.1M | $1.7M | $548.7K |
| FY2024 | $2.5M | $8.7M | $6.5M |
| FY2025 | $4.1M | $8.6M | $7.2M |